Assembly Biosciences (ASMB) Competitors $16.89 +0.08 (+0.48%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ASMB vs. SBBP, OMER, NKTR, CPIX, LXRX, GILD, LLY, JNJ, ABBV, and MRKShould you be buying Assembly Biosciences stock or one of its competitors? The main competitors of Assembly Biosciences include Strongbridge Biopharma (SBBP), Omeros (OMER), Nektar Therapeutics (NKTR), Cumberland Pharmaceuticals (CPIX), Lexicon Pharmaceuticals (LXRX), Gilead Sciences (GILD), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck & Co., Inc. (MRK). These companies are all part of the "medical" sector. Assembly Biosciences vs. Strongbridge Biopharma Omeros Nektar Therapeutics Cumberland Pharmaceuticals Lexicon Pharmaceuticals Gilead Sciences Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Strongbridge Biopharma (NASDAQ:SBBP) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation, community ranking and institutional ownership. Is SBBP or ASMB more profitable? Assembly Biosciences has a net margin of 0.00% compared to Strongbridge Biopharma's net margin of -115.67%. Strongbridge Biopharma's return on equity of -66.82% beat Assembly Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Strongbridge Biopharma-115.67% -66.82% -36.21% Assembly Biosciences N/A -121.55%-43.06% Do analysts rate SBBP or ASMB? Assembly Biosciences has a consensus price target of $35.00, indicating a potential upside of 107.22%. Given Assembly Biosciences' higher possible upside, analysts clearly believe Assembly Biosciences is more favorable than Strongbridge Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Strongbridge Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AAssembly Biosciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media favor SBBP or ASMB? In the previous week, Assembly Biosciences had 26 more articles in the media than Strongbridge Biopharma. MarketBeat recorded 26 mentions for Assembly Biosciences and 0 mentions for Strongbridge Biopharma. Assembly Biosciences' average media sentiment score of 0.08 beat Strongbridge Biopharma's score of 0.00 indicating that Assembly Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Strongbridge Biopharma Neutral Assembly Biosciences Neutral Do insiders & institutionals have more ownership in SBBP or ASMB? 52.0% of Strongbridge Biopharma shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 5.1% of Strongbridge Biopharma shares are owned by company insiders. Comparatively, 5.1% of Assembly Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community prefer SBBP or ASMB? Strongbridge Biopharma received 68 more outperform votes than Assembly Biosciences when rated by MarketBeat users. However, 58.98% of users gave Assembly Biosciences an outperform vote while only 49.60% of users gave Strongbridge Biopharma an outperform vote. CompanyUnderperformOutperformStrongbridge BiopharmaOutperform Votes31149.60% Underperform Votes31650.40% Assembly BiosciencesOutperform Votes24358.98% Underperform Votes16941.02% Which has more risk and volatility, SBBP or ASMB? Strongbridge Biopharma has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Which has stronger valuation & earnings, SBBP or ASMB? Strongbridge Biopharma has higher revenue and earnings than Assembly Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStrongbridge Biopharma$30.73M4.41-$45.08M-$0.78-2.56Assembly Biosciences$7.16M14.98-$61.23MN/AN/A SummaryStrongbridge Biopharma and Assembly Biosciences tied by winning 7 of the 14 factors compared between the two stocks. Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get Assembly Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASMB vs. The Competition Export to ExcelMetricAssembly BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$107.25M$7.03B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E RatioN/A9.93115.5615.18Price / Sales14.98381.421,484.3492.77Price / CashN/A47.3439.6634.07Price / Book2.255.324.665.02Net Income-$61.23M$153.56M$119.06M$225.46M7 Day Performance-0.12%0.11%0.80%0.37%1 Month Performance12.52%15.22%5.65%3.57%1 Year Performance61.76%41.14%36.76%29.44% Assembly Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASMBAssembly Biosciences4.4626 of 5 stars$16.89+0.5%$35.00+107.2%+58.7%$107.25M$7.16M0.00100Short Interest ↓SBBPStrongbridge BiopharmaN/A$2.00flatN/A+0.0%$135.66M$30.73M-2.6772Analyst ForecastGap DownOMEROmeros0.6943 of 5 stars$4.04-4.3%N/A+261.1%$234.11MN/A-1.72198NKTRNektar Therapeutics4.2982 of 5 stars$1.19-4.8%$2.33+96.1%+153.6%$219.05M$93.16M-1.32220Upcoming EarningsNews CoverageCPIXCumberland Pharmaceuticals0.5882 of 5 stars$1.12-5.9%N/A-37.1%$15.79M$37.79M-1.5380Upcoming EarningsAnalyst ForecastHigh Trading VolumeLXRXLexicon Pharmaceuticals1.9435 of 5 stars$1.95-3.9%$8.00+310.3%-9.0%$480.16M$3.64M-2.50285Analyst ForecastNews CoverageGap DownGILDGilead Sciences4.9366 of 5 stars$88.82+0.6%$86.85-2.2%+11.6%$110.66B$27.81B108.3218,000Upcoming EarningsAnalyst ForecastLLYEli Lilly and Company4.9073 of 5 stars$829.84-2.0%$1,009.00+21.6%+47.7%$788.68B$38.92B102.2043,000Earnings ReportDividend AnnouncementAnalyst ForecastAnalyst RevisionHigh Trading VolumeJNJJohnson & Johnson4.886 of 5 stars$159.86-0.5%$175.93+10.1%+7.7%$384.73B$87.70B23.13131,900Short Interest ↓ABBVAbbVie4.8525 of 5 stars$203.87+1.2%$199.39-2.2%+42.9%$360.01B$55B67.9650,000Earnings ReportDividend IncreaseAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageMRKMerck & Co., Inc.4.9993 of 5 stars$102.32-2.4%$131.46+28.5%-1.0%$259.16B$60.12B18.9872,000Earnings ReportAnalyst ForecastNews Coverage Related Companies and Tools Related Companies Strongbridge Biopharma Alternatives Omeros Alternatives Nektar Therapeutics Alternatives Cumberland Pharmaceuticals Alternatives Lexicon Pharmaceuticals Alternatives Gilead Sciences Alternatives Eli Lilly and Company Alternatives Johnson & Johnson Alternatives AbbVie Alternatives Merck & Co., Inc. Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ASMB) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assembly Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assembly Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
